Manifestation of leukoencephalopathy in a patient with advanced non-small cell lung cancer following treatment with gefitinib

被引：2

作者：

Huang Yi-sheng ^{[1
]}

Huang Biao ^{[2
]}

Wu Yi-long ^{[1
]}

机构：

[1] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou 510080, Guangdong, Peoples R China

[2] Guangdong Gen Hosp, Dept Radiol, Guangzhou 510080, Guangdong, Peoples R China

来源：

CHINESE MEDICAL JOURNAL | 2011年 / 124卷 / 22期

关键词：

gefitinib; leukoencephalopathy; radiosensitizing; non-small cell lung cancer; RECEPTOR-TYROSINE KINASE; CENTRAL-NERVOUS-SYSTEM; RADIATION; BRAIN; INHIBITOR; NEUROTOXICITY; CHEMOTHERAPY; METHOTREXATE; RADIOTHERAPY; SURVIVAL;

D O I：

10.3760/cma.j.issn.0366-6999.2011.22.043

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The present case is a patient with advanced non-small cell lung cancer (NSCLC) who developed leukoencephalopathy following radiotherapy and gefitinib treatments. There are rarely reports of such incidences because the median survival period of advanced NSCLC is only ten months. The features of leukoencephalopathy in this case were atypical for radiation leukoencephalopathy, so it was suspected that the leukoencephalopathy was associated with gefitinib. Chin Med J 2011;124(22):3834-3837

引用

页码：3834 / 3837

页数：4

共 50 条

[21] Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment
Song Zheng-bo
Yu Yong-feng
Chen Zhi-wei
Lu Shun
CHINESE MEDICAL JOURNAL, 2011, 124 (15) : 2279 - 2283
[22] Phase II Study of Erlotinib for Acquired Resistance to Gefitinib in Patients with Advanced Non-small Cell Lung Cancer
Horiike, Atsushi
Yamamoto, Nobuyuki
Tanaka, Hisashi
Yanagitani, Noriko
Kudo, Keita
Ohyanagi, Fumiyoshi
Ono, Akira
Naito, Tateaki
Murakami, Haruyasu
Horai, Takeshi
Nishio, Makoto
ANTICANCER RESEARCH, 2014, 34 (04) : 1975 - 1981
[23] Frontline gefitinib in advanced non-small cell lung cancer: Meta-analysis of published randomized trials
Ibrahim, Ezzeldin M.
ANNALS OF THORACIC MEDICINE, 2010, 5 (03) : 153 - 160
[24] Gefitinib and docetaxel for the treatment of non-small cell lung cancer: a meta-analysis
Yu, Huiqing
Zhang, Aihong
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (11): : 21057 - 21065
[25] Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib
Asahina, Hajime
Oizumi, Satoshi
Inoue, Akira
Kinoshita, Ichiro
Ishida, Takashi
Fujita, Yuka
Sukoh, Noriaki
Harada, Masao
Maemondo, Makoto
Saijo, Yasuo
Dosaka-Akita, Hirotoshi
Isobe, Hiroshi
Nukiwa, Toshihiro
Nishimura, Masaharu
ONCOLOGY, 2010, 79 (5-6) : 423 - 429
[26] First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status
Lee, Young Joo
Kim, Heung Tae
Han, Ji-Youn
Yun, Tak
Lee, Geon Kook
Kim, Hyae Young
Sung, Ji-Hyun
Lee, Jin Soo
JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (03) : 361 - 368
[27] Impact of gefitinib in early stage treatment on circulating cytokines and lymphocytes for patients with advanced non-small cell lung cancer
Sheng, Jin
Fang, Wenfeng
Liu, Xia
Xing, Shan
Zhan, Jianhua
Ma, Yuxiang
Huang, Yan
Zhou, Ningning
Zhao, Hongyun
Zhang, Li
ONCOTARGETS AND THERAPY, 2017, 10 : 1101 - 1110
[28] Pharmacokinetic analysis of gefitinib in a patient with advanced non-small cell lung cancer undergoing hemodialysis
Luo, Jinmei
Ni, Li
Wang, Mengzhao
Zhong, Wei
Xiao, Yi
Zheng, Ke
Hu, Pei
THORACIC CANCER, 2016, 7 (02) : 251 - 253
[29] Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer
Horiike, A.
Kudo, K.
Miyauchi, E.
Ohyanagi, F.
Kasahara, K.
Horai, T.
Nishio, M.
BRITISH JOURNAL OF CANCER, 2011, 105 (08) : 1131 - 1136
[30] Locally Advanced, Unresectable Non-Small Cell Lung Cancer
Puri, Sonam
Saltos, Andreas
Perez, Bradford
Le, Xiuning
Gray, Jhanelle E.
CURRENT ONCOLOGY REPORTS, 2020, 22 (04)

← 1 2 3 4 5 →